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approximation of the energy deposited by each individual 
proton in each layer. 
A tracking algorithm is able to find the water equivalent path 
length of each individual proton. When this information is 
combined with the approximated energy deposition on each 
layer, an estimate of the incoming proton energy is obtained 
by locating the high energy deposit of the Bragg Peak. 
Results from this analysis, as well as the capabilities of 
alternative setups will be presented, to show the feasibility 
of using such a calorimeter for proton Computed 
Tomography. 
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Purpose: The more selective energy deposition of protons in 
depth is advantageous compared to photons to preserve 
normal tissues. Nevertheless, an even better tissue sparing 
might be possible in proton therapy if combined with the 
well-established tissue preservation of spatially fractionated 
submillimetric beams. This sparing effect has been observed 
in studies performed with synchrotron minibeam 
radiotherapy (MBRT) [1,2].  
The innovative approach proposed here, called proton 
minbeam radiation therapy (pMBRT), was shown to lead to 
favorable dose distributions in Monte Carlo (MC) studies [3]. 
The dose profiles in normal tissue consist in peaks and 
valleys, while the tumour receives a (quasi)-homogenous 
dose distribution [3]. The goal of this study was to implement 
this promising approach at a clinical center, as well as to 
gather a complete set of dosimetric data that will serve to 
guide the ongoing biological experiments [4].  
Material and Methods: The implementation of pMBRT was 
carried out at the Proton Therapy Center in Orsay (ICPO). 100 
MeV-proton minibeams (400 and 700 μm-width) were 
generated by means of a multislit collimator. The dose 
distributions (depth dose curves, lateral profiles, peak-to-
valley dose ratios (PVDR) [6], beam widths and output 
factors) were measured by means of Gafchromic EBT3 films 
and the new PTW microDiamond detector [5].  
In parallel, a very first MC-based calculation engine for 
pMBRT is under development using Gate v7.0. 
Results: The experimental data confirm that a spatial 
fractionation of the dose is maintained in normal tissues 
(PVDR up to 7) while a quasi-homogeneous dose distribution 
is reached at the Bragg peak location, in agreement with 
theoretical predictions [3]. The reduced penumbras (600-
1100 μm) in healthy tissue make pMBRT a good candidate for 
radiosurgery applications.  
Similar results were obtained using either EBT3 films or the 
PTW microDiamond detector. The preliminary MC 
calculations were consistent with experimental dose 
distributions.  
Conclusion: This is the first work providing both a complete 
set of dosimetric data in such small proton field sizes and a 
practical implementation of this promising approach using a 
clinical set-up and beam energy. The dose distributions 
showed the potential of this technique, which might lead to a 
reduction of the normal tissue complication probability. 
Animal irradiation experiments are ongoing to confirm the 
normal tissue sparing capability of pMBRT. 
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Purpose: We assessed in vitro and in vivo the relative 
contribution of direct and bystander effects in the 
therapeutic efficacy of RIT using 212Pb-labeled mAbs for 
treating cancer cells.  
Materials and Methods: A-431 cells were in vitro exposed to 
increasing activities (0–0.5 MBq/mL; 37 MBq/mg) of either 
35A7 (anti-CEA), Trastuzumab (anti-HER2) or PX (non-
specific) 212Pb-labeled mAbs. The relative contribution of 
direct and bystander effects was determined using standard 
medium transfer protocol. Biological end points included 
clonogenic survival and DNA double strand breaks (using 
53BP1 and gamma-H2AX immunofluorescence detection) 
measured both in donor (direct effect) and in recipient cells 
(bystander effects). In vivo, nude mice with intraperitoneal 
(i.p.) 2-3 mm A-431 tumour cells xenografts were i.p. 
injected with increasing activities (370–1480 kBq; 37 
MBq/mg) of the above mentioned anti-CEA, anti-HER2 or non-
specific 212Pb-mAbs. Tumour growth was determined and the 
distribution of radioactivity at the tissue level was assessed 
using digital micro-autoradiography (DAR) followed by voxel 
dosimetry. Biological markers including 53BP1 and Ki67 
proteins together with abnormal mitosis were also 
determined on tumour sections. 
Results: In vitro we showed in donor cells the strong efficacy 
of 212Pb-35A7 and 212Pb-trastuzumab mAbs and also to a lower 
extent of 212Pb-PX mAb. Significant bystander cytotoxicity 
was measured in all recipient cells with the three 
radiolabeled mAbs. The complexity of DNA damage (53BP1 
foci) observed in donor cells confirmed the high LET 
cytotoxic effects of 212Pb-mAbs while less complex damage 
were observed in recipient cells. 
In vivo DAR and voxel dosimetry indicated the strong 
heterogeneity in anti-CEA 212Pb-mAbs distribution in tumours. 
Conversely, distribution of anti-HER2 212Pb-mAbs was much 
more homogeneous. These data could explain the lower 
therapeutic efficacy of the latter mAbs compared with anti-
HER2 212Pb-mAbs (median survival of 94 days for anti-CEA 
212Pb-mAbs versus 20 days for control, not reached for anti-
HER2 212Pb-mAbs). Moreover, voxel dosimetry indicated that 
about 30% of the tumours of mice treated with anti-CEA 
212Pb-mAbs received 0Gy. However, we also observed in the 
same tumours, homogeneous formation of DNA damage 
